Cart summary

You have no items in your shopping cart.

MC-Sq-Cit-PAB-Gefitinib

SKU: orb1988055

Description

MC-Sq-Cit-PAB-Gefitinib is an antibody-drug conjugate (ADC) linker-payload conjugate featuring the EGFR inhibitor Gefitinib. This construct is designed for developing ADCs to target EGFR-driven cancers, enabling research into targeted drug delivery and efficacy in both in vitro and in vivo models.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number1941168-63-3
MW1000.53
FormulaC50H61ClFN10O9
SMILESN(C=1C2=C([N+](CC3=CC=C(NC([C@@H](NC(=O)C4(C(NCCCCCN5C(=O)C=CC5=O)=O)CCC4)CCCNC(N)=O)=O)C=C3)=CN1)C=C(OC)C(OCCCN6CCOCC6)=C2)C7=CC(Cl)=C(F)C=C7
TargetPROTAC Linker,Drug-Linker Conjugates for ADC

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

MC-Sq-Cit-PAB-Gefitinib (orb1988055)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%